Corcept Therapeutics is a pharmaceutical company engaged in the development of medications for the treatment of Cushing’s Syndrome, as well as severe psychiatric and metabolic disease.  The SEISMIC study is an open-label Phase III multi-center clinical trial to examine the efficacy of CORLUX in treating patients with endogenous Cushing’s Syndrome.